Abstract:Background: The identification of compound-protein interactions (CPIs) is crucial for drug discovery and understanding mechanisms of action. Accurate CPI prediction can elucidate drug-target-disease interactions, aiding in the discovery of candidate compounds and effective synergistic drugs, particularly from traditional Chinese medicine (TCM). Existing in silico methods face challenges in prediction accuracy and generalization due to compound and target diversity and the lack of largescale interaction datasets and negative datasets for model learning. Methods: To address these issues, we developed a computational model for CPI prediction by integrating the constructed large-scale bioactivity benchmark dataset with a deep learning (DL) algorithm. To verify the accuracy of our CPI model, we applied it to predict the targets of compounds in TCM. An herb pair of Astragalus membranaceus and Hedyotis diffusaas was used as a model, and the active compounds in this herb pair were collected from various public databases and the literature. The complete targets of these active compounds were predicted by the CPI model, resulting in an expanded target dataset. This dataset was next used for the prediction of synergistic antitumor compound combinations. The predicted multi-compound combinations were subsequently examined through in vitro cellular experiments. Results: Our CPI model demonstrated superior performance over other machine learning models, achieving an area under the Receiver Operating Characteristic curve (AUROC) of 0.98, an area under the precision-recall curve (AUPR) of 0.98, and an accuracy (ACC) of 93.31% on the test set. The model's generalization capability and applicability were further confirmed using external databases. Utilizing this model, we predicted the targets of compounds in the herb pair of Astragalus membranaceus and Hedyotis diffusaas, yielding an expanded target dataset. Then, we integrated this expanded target dataset to predict effective drug combinations using our drug synergy prediction model DeepMDS. Experimental assay on breast cancer cell line MDA-MB-231 proved the efficacy of the best predicted multi-compound combinations: Combination I (Epicatechin, Ursolic acid, Quercetin, Aesculetin and Astragaloside IV) exhibited a half-maximal inhibitory concentration (IC50) value of 19.41 μM, and a combination index (CI) value of 0.682; and Combination II (Epicatechin, Ursolic acid, Quercetin, Vanillic acid and Astragaloside IV) displayed a IC50 value of 23.83 μM and a CI value of 0.805. These results validated the ability of our model to make accurate predictions for novel CPI data outside the training dataset and evaluated the reliability of the predictions, showing good applicability potential in drug discovery and in the elucidation of the bioactive compounds in TCM. Conclusion: Our CPI prediction model can serve as a useful tool for accurately identifying potential CPI for a wide range of proteins, and is expected to facilitate drug research, repurposing and support the understanding of TCM.

Predicting the activity of drugs for a group of imidazopyridine anticoccidial compounds.

Qsar Models for the Dermal Penetration of Polycyclic Aromatic Hydrocarbons Based on Gene Expression Programming

Quantitative structure activity relationship model for predicting the depletion percentage of skin allergic chemical substances of glutathione.

Improved Gene Expression Programming and Its Application to QSAR

Modeling drug mechanism of action with large scale gene-expression profiles using GPAR, an artificial intelligence platform

Predicting cell morphological responses to perturbations using generative modeling

Deep learning-driven prediction of drug mechanism of action from large-scale chemical-genetic interaction profiles

Learning the Cellular Activity Representation Based on Gene Regulatory Networks for Prediction of Tumor Response to Drugs

Evaluation of gene-drug common module identification methods using pharmacogenomics data

A general prediction model for compound-protein interactions based on deep learning

In silico gene function prediction using ontology-based pattern identification

DRUGSYNC: Prediction of Synergistic Drug Combinations Using GCN Graph Convolutional Network based and Pre-learned Drug-induced Gene Expression Profiles

A multitask interpretable model with graph attention mechanism for activity prediction of low-data PIM inhibitors

REP: Predicting the Time-Course of Drug Sensitivity

ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques.

DeSIDE-DDI: interpretable prediction of drug-drug interactions using drug-induced gene expressions

Prediction of protein–protein interactions based on elastic net and deep forest

Applications of Genetic Algorithms on the Structure–activity Correlation Study of a Group of Non-Nucleoside HIV-1 Inhibitors

Machine learning to predict metabolic drug interactions related to cytochrome P450 isozymes

Activity prediction of hepatitis C virus NS5B polymerase inhibitors of pyridazinone derivatives

MT-EpiPred: Multitask Learning for Prediction of Small-Molecule Epigenetic Modulators